OLUMIANT Market Drug Insight and Market Forecast - 2032

“OLUMIANT Market Drug Insight and Market Forecast - 2032” report provides comprehensive insights about OLUMIANT for Atopic Dermatitis (AD) in the seven major markets. A detailed picture of the OLUMIANT for atopic dermatitis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the OLUMIANT for atopic dermatitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the OLUMIANT market forecast analysis for atopic dermatitis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in atopic dermatitis.

Drug Summary

Baricitinib (LY3009104) - discovered by Incyte and developed under license by Lilly and marketed as OLUMIANT - is an oral selective Janus kinase (JAK) 1/JAK2 inhibitor. It inhibits several cytokines in atopic dermatitis (AD) pathogenesis, including thymic stromal lymphopoietin, IL-4, IL-5, IL-13, IL-22, and IL-31. The drug works by blocking the action of enzymes known as JAK1/JAK2 inhibitor that mediate the pathways involved in the inflammatory process in AD. In addition, the drug is already approved in EU for the treatment of moderate and severe AD. It is the first medicine for moderate and severe AD that patients can be taken orally. It is also approved in over 40 countries for the treatment of adults with moderate to severe AD who are candidates for systemic therapy.

Eli Lilly and partner Incyte have filed a regulatory review for JAK inhibitor Olumiant to treat AD in the US. However, the marketing authorization holder for Olumiant is Eli Lilly Nederland.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the OLUMIANT description, mechanism of action, dosage and administration, research and development activities in atopic dermatitis.
• Elaborated details on OLUMIANT regulatory milestones and other development activities have been provided in this report.
• The report also highlights the OLUMIANT research and development activities in atopic dermatitis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around OLUMIANT.
• The report contains forecasted sales of for atopic dermatitis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for atopic dermatitis.
• The report also features the SWOT analysis with analyst views for OLUMIANT in atopic dermatitis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

OLUMIANT Analytical Perspective

In-depth OLUMIANT Market Assessment

This report provides a detailed market assessment of OLUMIANT for atopic dermatitis in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

OLUMIANT Clinical Assessment

The report provides the clinical trials information of OLUMIANT for atopic dermatitis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for atopic dermatitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OLUMIANT dominance.
• Other emerging products for atopic dermatitis are expected to give tough market competition to OLUMIANT and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of OLUMIANT in atopic dermatitis.
• This in-depth analysis of the forecasted sales data of OLUMIANT from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the OLUMIANT in atopic dermatitis.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of OLUMIANT?
• What is the clinical trial status of the study related to OLUMIANT in atopic dermatitis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OLUMIANT development?
• What are the key designations that have been granted to OLUMIANT for atopic dermatitis?
• What is the forecasted market scenario of OLUMIANT for atopic dermatitis?
• What are the forecasted sales of OLUMIANT in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to OLUMIANT for atopic dermatitis?
• Which are the late-stage emerging therapies under development for the treatment of atopic dermatitis?

This product will be delivered within 2 business days.